News

FDA has approved Terlipressin injection to improve kidney function in adults with hepatorenal syndrome (HRS) with rapid reduction in kidney function. Terlipressin is the first FDA-approved medication for this condition.   Disease or Condition HRS is characterized by a progressive deterioration in kidney function in people with advanced liver disease. This is most common in those with advanced cirrhosis (liver scarring) and ascites, an abnormal buildup of fluid in the abdomen that is often related to liver disease. The prognosis is very poor, particularly if patients’ liver disease is not treated with liver transplantation. Rising levels of serum creatinine (a waste product in the blood) in patients with HRS can indicate worsening kidney function. Effectiveness The effectiveness of Terlipressin was assessed in a double-blind study. Participants with HRS with rapid reduction in kidney function were randomly assigned to receive Terlipressin (199 participants) or a placebo (101 participants). Participants received either 0.85 mg of Terlipressin or a placebo every six hours as an injection in the vein for a maximum of 14 days. The dose was adjusted based on changes in kidney function. The primary effectiveness outcome was the percentage of patients who had kidney function improvement, defined by two consecutive days of serum creatinine levels of 1.5 mg/dL or less, obtained at least two hours apart, by day 14 or the participant’s final day in the study. Twenty-nine percent of participants in the Terlipressin group had kidney function improvement compared to 16 percent of participants in the placebo group. People with serum creatinine levels of 5 mg/dL or greater should not take Terlipressin because they are unlikely to benefit from treatment. Safety Information Terlipressin increases the risk of serious or fatal respiratory (breathing) failure. Patients with low oxygen in their blood should not start the medication. During treatment, patients should be monitored for breathing problems with a pulse oximeter — a tool that measures oxygen levels in the blood. Side effects of Terlipressin may prevent patients from receiving a liver transplant. Terlipressin can cause ischemic events (that occur when blood does not reach certain parts of the body) that may require pausing or stopping treatment; the medication may also cause fetal harm when used during pregnancy. The most common side effects include abdominal pain, nausea, diarrhea, respiratory failure, and dyspnea (difficulty breathing). Our Product Terlipressin for Injection 1mg Grand Life Sciences (Liaoning) Co., Ltd. offers medicines in a variety of therapeutic areas, including Hemostasis, Anesthesia, Analgesia, Wound Management and Nutritional Supplements.  Feel free to contact us for more information.

On June 21, 2024, the 22nd CPHI China and the 17th PMEC China successfully concluded at the Shanghai New International Expo Centre. Over the course of three days, CPHI & PMEC China 2024 attracted a total of 99,749 visitors, with nearly 25% being international attendees, marking a 41.4% increase from 2023. These visitors hailed from 135 countries and regions, setting a new record and further enhancing the event's international influence and appeal.At Booth E3A01, Grand Life Sciences (Liaoning) Co., Ltd. showcased its products and solutions in the fields of hemostasis, anesthesia, analgesia, wound management and nutritional supplements with enthusiasm and professionalism to clients and partners from various countries. During this prominent pharmaceutical event, over a hundred domestic and international companies visited our booth to inquire about product information and exchange business cards, significantly advancing our strategic layout for expanding into overseas markets. We engaged in information exchanges and business discussions with representatives from many companies in Asia, Europe, Africa, and South America, initiating preliminary negotiations on product distribution and business cooperation with some of them.This exhibition not only demonstrated our company's strength and determination to enter the global market but also provided insights into the latest trends and demands of the international market, laying a solid foundation for future business expansion. Through interactions with international peers, GLS Liaoning discovered more potential cooperation opportunities and looks forward to deepening cooperation with both new and existing clients. We are committed to delivering higher-quality medical solutions to patients worldwide.

Recently, Shenyang has continued to experience high temperatures. On August 23rd, one of the twenty-four solar terms in China - the limit of heat, the high temperature in the afternoon made the employees feel tired and sleepy. In order to give coolness to the hard-working employees in various positions, the Human Resources Department of Grand Life Sciences (Liaoning) Co., Ltd. set up a "Summer Dessert Station" at the reception lobby of the office building to deliver drinks and desserts to everyone, attracting more than 200 employees from the factory. In addition, August 22 this year is Chinese Valentine's Day. In Penglai Nuokang Pharmaceutical Co. Ltd., the company leaders decided to make yogurt cups to present this gift of love to employees who are busy with production and administrative services. At 10:00 in the morning, the leaders and managers of the company started the intensive production of yogurt cups, cutting fruit, packing yogurt, boxing, decoration, delivery, etc. Everyone worked together, and soon completed the production and distribution of those loving yogurt cups. The purpose of this activity is to carry forward Chinese traditional culture, convey the sense of happiness of the Nuokang family, and promote the healthy growth of modern family concepts. As a well-known pharmaceutical manufacturer in China, Grand Life Sciences (Liaoning) Co., Ltd. aims to provide high-quality and competitive pharmaceuticals to people around the world, including hemostatic products, analgesic products, anesthesia products, nutritional supplements, etc.

Recently, Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (hereinafter referred to as "Shuyang") won the title of 2022 Chengdu Industrial Tourism Demonstration Site. Yuanda Shuyang is the first industrial tourism base of Chengdu pharmaceutical companies, and has become a new landmark of Chengdu industrial tourism. After visiting Shuyang's "Tree of Life" art exhibition, "Journey of Life" enterprise exhibition hall, and blood product production line, the leader of the preparatory group of Sichuan Industrial Culture Development Association Cai Jing highly affirmed Shuyang's exploration and future development planning in industrial tourism and cultural construction. He said that the rise of the biopharmaceutical industry is of great significance to improving people's quality of life. As a subdivision of biopharmaceuticals, the blood product industry plays an important clinical role in the fields of intensive care, rare diseases, and immune system diseases. It is hoped that Shuyang will continue to invest in R&D and innovation to promote the development of high-end manufacturing industries. The manufacturing base of Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. is located at No. 888, 5th Antai Road, High-tech Zone, Chengdu. The base has a total investment of more than 2 billion RMB and complies with China GMP and EU GMP standards. It can simultaneously produce blood products for three major categories of plasma sources: human albumin, immunoglobulin, and coagulation factors. Yuanda Shuyang Pharmaceutical Co., Ltd. will combine biomedical health culture and citizens' leisure and tourism needs to further enrich tourism content, and at the same adhere to the core of R&D and innovation, and contribute our strength to the progress of human health.

On July 16, the walking activity of Grand Life Science (Liaoning) Co., Ltd. was held in Mozishan Park, Shenyang. Huang Ling, chairman of the company, Liu Liping, deputy general manager and CFO, Dong Jing, general manager of Penglai Nuokang, Zhang Lei, general manager of Liaoning Weibang, and other leaders attended the event. Although it rained during this activity, it did not affect everyone's enthusiasm at all. With the sound of the command, all participants set off from the starting point. Everyone's laughter blended with the scenery along the way. The track is 7.16 km long, and 3 group games are interspersed in the middle, which not only tests everyone's physical strength and perseverance, but also tests the communication and cooperation skills. These projects fully embody the team spirit of unity, fearlessness and close cooperation. After reaching the finish line, everyone went to the finishing area to take group photos together to record this exciting and unforgettable moment. At the awards ceremony, Chairman Huang Ling and other leaders presented prizes to the champion team and other outstanding teams, affirming and encouraging everyone's performance in the activity. Although the walking activity is over, the struggle of Grand Life Sciences will never stop. The successful holding of this activity has enhanced team cohesion and combat effectiveness. We believe that everyone will contribute to the development of the company with fuller enthusiasm and positive attitude. Grand Life Sciences (Liaoning) Co., Ltd. is a major member of China Grand Enterprises, providing perioperative high-end preparations and medical devices made of biodegradable materials. The company has an innovative drug R&D center, a high-tech barrier emulsion R&D center, and an enzymatic engineering transformation platform, and is supported by a modern production base, an API base, and a Peruvian snake venom supply base. Now we are concentrating on the chemical medicine export business, aims to provide high-quality and competitive pharmaceuticals to people around the world, including hemostatic products, analgesic products, anesthesia products, nutritional supplements, etc. please contact us if you are interested.

From July 7 to 9, 2023, the first Shuyang Human Immunoglobulin-Neural Expert Academic Conference "2023 Human Immunoglobulin Neuroimmune Expert Advisory Meeting" was successfully held in Chengdu. With the purpose of exploring the future research direction of human immunoglobulin and promoting the rational and standardized drug use in clinical practice, the meeting carried out wonderful academic content sharing and panel discussions. During the meeting, the experts jointly discussed the differences in the application of human immunoglobulin between China and foreign countries, and offered suggestions for the academic promotion of human immunoglobulin. At the beginning of the conference, Professor Dong Huiqing, the chairman of the conference, and Feng Zenghui, chairman of Grand Life Sciences Group, delivered speeches respectively. Professor Dong welcomed all the guests attending the conference, and thanked Shuyang for the academic platform, and hoped to have more cooperation with Shuyang in the future. Chairman Feng introduced the company's development history and future development plan, and at the same time expressed Shuyang's willingness to continue exploring in the field of neuroimmunology. Then Fu Zhengming, deputy general manager of Shuyang Marketing Center, introduced the company, focusing on the history of Shuyang, the establishment of the new factory and the advantages of human immunoglobulin. In the topic sharing session, Professor Lu Zuneng from People's Hospital of Wuhan University shared the first topic "Overview of the Application of IVIG in Neuroimmune Diseases", focusing on the application value of human immunoglobulin in the entire neuroimmune field. In the second topic, Professor Huang Tianwen from Fujian Medical University Union Hospital shared "Current Status of Diagnosis and Treatment of CIDP and Exploration of IVIG Opportunities", focusing on the current status of diagnosis and treatment of CIDP, the evidence-based basis and existing research of human immunoglobulin in CIDP. Through this expert advisory meeting, Shuyang Company completed the national-level expert network construction in the field of neuroimmunology, which opened a good start for further deepening the field of neurology. The meeting preliminarily clarified the current and future pattern of human immunoglobulin in neuroimmunology, and provided ideas for Shuyang product layout.

Grand Life Sciences Group Co., Ltd. (hereinafter referred to as "GLS ") is a modern pharmaceutical enterprise group, which integrates R&D, production and sales, and focuses on immunity, infection, severe disease, blood system, digestion and wound management, etc. The group has R&D centers and production bases in more than ten cities including Beijing, Chengdu, Hangzhou, Shenyang, Wuhan, Chongqing, Nanjing, Zhengzhou, Yantai, Anshan, etc., and is committed to the research and development of high-end blood products, chemical drugs, new recombinant vaccines, nano-targeted preparations, degradable medical devices and high-value raw materials. In the field of blood products, GLS owns Yuanda Shuyang Pharmaceutical Co., Ltd, one of the top 20 biopharmaceutical companies in China, and the production capacity of its newly built modern factory ranks first in Asia and among the top 10 in the world. The factory not only complies with Chinese GMP standards, but also meets EU and WHO standards. Shuyang products have covered the domestic market and exported to more than 10 countries. In 2021, with the approval of the National Medical Products Administration (NMPA) for the human fibrinogen product, Yuanda Shuyang Pharmaceutical has taken an important step in the field of blood coagulation factors. In the future, it will focus on the development of the full product line of blood products and continue to dig deeper in rare diseases. In the field of chemical medicine, GLS relies on the four major industrial bases of Grand Life Sciences (Liaoning), Grand Life Sciences (Wuhan), Penglai Nuokang and Liaoning Weibang. The company gives full play to the advantages of large industrial foundation and the raw materials-preparations integration to create nano-target R&D center, enzymatic engineering and polymer material R&D platform, API base and Peruvian snake venom supply base, and is committed to providing original biological drugs, emulsions, high-end preparation products and biodegradable medical devices. Focus on developing perioperative product groups, including hemostasis, anesthesia, analgesia, and anticoagulant drugs. Among them, Hemocoagulase Bothrops Atrox for Injection is the product with the largest share in the domestic hemostatic market, Flurbiprofen Axetil is the first domestically-made targeted analgesic injection, and Collagenase Ointment is currently the only enzymatic debridement drug officially approved at home and abroad. As a well-known pharmaceutical manufacturer in China, Grand Life Sciences (Liaoning) Co., Ltd. aims to provide high-quality and competitive pharmaceuticals to people around the world, including hemostatic products, analgesic products, anesthesia products, nutritional supplements, etc.